Rigel Pharmaceuticals

Rigel Pharmaceuticals' Products

Rigel Pharmaceuticals specializes in developing novel therapies for hematologic disorders and cancer. Key products include TAVALISSE (fostamatinib disodium hexahydrate), indicated for thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP), and REZLIDHIA (olutasidenib) capsules, targeted at adult patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation. These therapies highlight Rigel's commitment to addressing unmet medical needs in hematologic conditions.

Rigel Pharmaceuticals' Collaborative Partnerships

Rigel Pharmaceuticals has formed strategic partnerships with several industry leaders, including BerGenBio, Daiichi-Sankyo, Grifols, Kissei, Knight, Lilly, Medison, and Novo Nordisk. Notably, Rigel has entered into a global exclusive license agreement with Lilly for RIPK1 inhibitor programs and an exclusive license and supply agreement with Knight for fostamatinib's commercialization in Latin America. These collaborations leverage Rigel's innovative research to enhance global healthcare solutions.

Rigel Pharmaceuticals' Proprietary Programs

Rigel Pharmaceuticals' proprietary programs focus on developing inhibitors for IRAK1/4 and RIPK1. Their pipeline includes R552, a systemic molecule targeting autoimmune and inflammatory disorders, and R289, an oral, potent, and selective inhibitor of interleukin receptor-associated kinases 1 and 4 (IRAK1/4). R289 is currently in a Phase 1b open-label, multicenter trial for patients with relapsed/refractory lower-risk myelodysplastic syndrome (LR-MDS). These programs underscore Rigel’s innovative approach to addressing complex diseases.

Rigel Pharmaceuticals' Global Reach

Rigel Pharmaceuticals has expanded its global footprint through various exclusive license and supply agreements. For instance, the company has partnered with Kissei to develop and commercialize fostamatinib in Japan, China, Taiwan, and the Republic of Korea, and with Grifols to commercialize the same in Europe and Turkey. Additionally, Grifols has expanded its territory to include the Middle East, North Africa, Russia, and CIS. Such agreements ensure that Rigel's groundbreaking therapies are accessible to patients worldwide.

Rigel Pharmaceuticals' Regulatory Approvals

Rigel Pharmaceuticals has achieved significant regulatory milestones, including approval from Health Canada for fostamatinib for treating thrombocytopenia in adults with chronic immune thrombocytopenia (ITP). Additionally, the Israel Ministry of Health has approved TAVALISSE for ITP treatment. These approvals validate the safety and efficacy of Rigel's therapies, facilitating their adoption in critical markets and expanding treatment options for patients.